English
Nederlands (België)
A PLASMA-BASED NANOTECHNOLOGY TO KILL SARS COV2 VIRUS
DISCOVER THE TECHNOLOGYA plasma-based nanotechnology inactivates
all airborne micro-organisms, Sars-Cov2 virus and bacteria.
The First Line of Protection Against Airborne Viruses and Bacteria
Developed by the Novaerus team of scientists and engineers, NanoStrike utilizes an atmospheric plasma discharge — the same type of discharge found in lightning strikes — to kill and deactivate harmful airborne microorganisms.
NanoStrike plasma coils provide a deadly strike, made up of multiple concurrent inactivation processes, that work to rapidly destroy airborne pathogens such as viruses, bacteria and fungi.
Microorganisms are exposed directly to the plasma discharge as opposed to by-products of the discharge as the air flows over the coils.
Lowest total cost of ownership of any air purification technology
Powerful but gentle for 24/7 use around the most vulnerable of people
Laboratory & Clinical Research Summary
In independent laboratory studies Novaerus products, powered by NanoStrike
technology, have been shown to safely and effectively reduce bacteria, mould spores, viruses, allergens, volatile organic compounds, and particulate matter.
In clinical settings, Novaerus products have been demonstrated to reduce airborne pathogens, surface bacteria, virus (SARS-CoV2 / Influenza A....), infections, antibiotic use, and odours.
technology, have been shown to safely and effectively reduce bacteria, mould spores, viruses, allergens, volatile organic compounds, and particulate matter.
In clinical settings, Novaerus products have been demonstrated to reduce airborne pathogens, surface bacteria, virus (SARS-CoV2 / Influenza A....), infections, antibiotic use, and odours.
LAB STUDY - SARS-COV-2 REDUCTION
The Defend 1050 achieved a 4,53 log10 reduction of live SARS-CoV-2 virus, which equates to a 99,997% percentage reduction in 30 minutes. The live SARS-CoV-2 virus was not detectable after 30 minutes.
READ MORE
The Defend 1050 achieved a 4,53 log10 reduction of live SARS-CoV-2 virus, which equates to a 99,997% percentage reduction in 30 minutes. The live SARS-CoV-2 virus was not detectable after 30 minutes.
READ MORE
LAB STUDY - AIRBORNE BIOAEROSOLS REDUCTION
Novaerus Protect 800 was shown to reduce aerolized biologicals: Staphylococcus epidermidis (99,87% reduction), MS2 bacteriophage (99,99% reduction), Aspergillus niger fungus (99,1% reduction) and Bacillus subtilis endospores (86,63% reduction) at the Aerosol Research and Engineering Laboratories.
READ MORE
Novaerus Protect 800 was shown to reduce aerolized biologicals: Staphylococcus epidermidis (99,87% reduction), MS2 bacteriophage (99,99% reduction), Aspergillus niger fungus (99,1% reduction) and Bacillus subtilis endospores (86,63% reduction) at the Aerosol Research and Engineering Laboratories.
READ MORE
LAB STUDY - VOC REDUCTION
Novaerus Defend 1050 achieved 90% VOC removal after 6-16 minutes, dependent on fan speed at Camfil Laboratories - Tech Center in Sweden
READ MORE
Novaerus Defend 1050 achieved 90% VOC removal after 6-16 minutes, dependent on fan speed at Camfil Laboratories - Tech Center in Sweden
READ MORE
LAB STUDY - AIRBORNE ALLERGENS NEUTRALIZATION
Novaerus Protect 800 was shown to reduce overall allergens by 41,16%, including house dust mites, feline dander, canine dander and pollen at Indoor Biotechnologies Ltd. In Cardiff, UK.
READ MORE
Novaerus Protect 800 was shown to reduce overall allergens by 41,16%, including house dust mites, feline dander, canine dander and pollen at Indoor Biotechnologies Ltd. In Cardiff, UK.
READ MORE
This in vitro study characterized the efficacy of the Novaerus NV 1050 device at removing aerosolized Bacillus Globigii Endospores.... This study evaluated the efficacy of the device against aerosolized Bacillus Globigii as well as various sizes of polystyrene latex microspheres (PSL) in a stainless steel bioaerosol chamber. The study consisted of a total of four (4) live bioaerosol trials, single (1) bioaerosol control run plus three PSL (3) challenge trials as well as PSL control trials. All trials evaluated the NV 1050 device on the highest fan velocity setting with the exception of a 24 hour run reported in Appendix B.
SEE MORE
SEE MORE
EN VERSION
Novaerus Defend 1050 was shown to reduce MS2 bacteriophage virus, a surrogate for SARS-CoV-2, by 99,99% in 15 minutes at Aerosol Research and Engineering Laboratories
__________________
FR VERSION
Les études menées par le laboratoire Aerosol Research and Engineering** ont démontré l’efficacité sur le MS2 bactériophage, un substitut du COVID-19
Novaerus Defend 1050 was shown to reduce MS2 bacteriophage virus, a surrogate for SARS-CoV-2, by 99,99% in 15 minutes at Aerosol Research and Engineering Laboratories
__________________
FR VERSION
Les études menées par le laboratoire Aerosol Research and Engineering** ont démontré l’efficacité sur le MS2 bactériophage, un substitut du COVID-19
La Nasa, a démontré que la technologie brevetée Novaerus possède des propriétés uniques de destruction des micro-organismes*.
Novaerus Defend 1050 cleared by FDA as 510(k)
Class II Medical Device
Class II Medical Device
Defend 1050 uses patented NanoStrike® technology to damage and inactivate airborne micro-organisms.
The U.S. Food and Drug Administration (FDA) cleared the Novaerus Defend 1050 (NV 1050) as a 510(k) Class II Medical Device to inactivate and filter out micro-organisms, including virus and bacteria, for medical purposes. The Novaerus Defend 1050 is the first system that uses NanoStrike®, a patented plasma generating technology, to receive FDA 510(k) clearance...... The Defend 1050's NanoStrike technology uses a plasma field that rapidly inactivates micro-organisms at the molecular level. Within 15 minutes, the Defend 1050 has demonstrated a 4-log (99.99%) reduction of the MS2 bacteriophage RNA virus, an accepted surrogate for SARS-CoV-2. The Defend 1050 also showed a 4-log (99.99%) reduction in Bacillus Globigii endospores (bacterial spores) within 15 minutes, which was maintained over the prolonged operation (24 hours).
SEE MORE
The U.S. Food and Drug Administration (FDA) cleared the Novaerus Defend 1050 (NV 1050) as a 510(k) Class II Medical Device to inactivate and filter out micro-organisms, including virus and bacteria, for medical purposes. The Novaerus Defend 1050 is the first system that uses NanoStrike®, a patented plasma generating technology, to receive FDA 510(k) clearance...... The Defend 1050's NanoStrike technology uses a plasma field that rapidly inactivates micro-organisms at the molecular level. Within 15 minutes, the Defend 1050 has demonstrated a 4-log (99.99%) reduction of the MS2 bacteriophage RNA virus, an accepted surrogate for SARS-CoV-2. The Defend 1050 also showed a 4-log (99.99%) reduction in Bacillus Globigii endospores (bacterial spores) within 15 minutes, which was maintained over the prolonged operation (24 hours).
SEE MORE
